These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37759937)

  • 21. A novel insight into differential expression profiles of sporadic cerebral cavernous malformation patients with different symptoms.
    Eren Gozel H; Kök K; Ozlen F; Isler C; Pence S
    Sci Rep; 2021 Sep; 11(1):19351. PubMed ID: 34588521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models.
    Shi C; Shenkar R; Zeineddine HA; Girard R; Fam MD; Austin C; Moore T; Lightle R; Zhang L; Wu M; Cao Y; Gunel M; Louvi A; Rorrer A; Gallione C; Marchuk DA; Awad IA
    J Neuroimmune Pharmacol; 2016 Jun; 11(2):369-77. PubMed ID: 27086141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The multifaceted
    Valentino M; Dejana E; Malinverno M
    Genes Dis; 2021 Nov; 8(6):798-813. PubMed ID: 34522709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphisms in inflammatory and immune response genes associated with cerebral cavernous malformation type 1 severity.
    Choquet H; Pawlikowska L; Nelson J; McCulloch CE; Akers A; Baca B; Khan Y; Hart B; Morrison L; Kim H;
    Cerebrovasc Dis; 2014; 38(6):433-40. PubMed ID: 25472749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping endothelial-cell diversity in cerebral cavernous malformations at single-cell resolution.
    Orsenigo F; Conze LL; Jauhiainen S; Corada M; Lazzaroni F; Malinverno M; Sundell V; Cunha SI; Brännström J; Globisch MA; Maderna C; Lampugnani MG; Magnusson PU; Dejana E
    Elife; 2020 Nov; 9():. PubMed ID: 33138917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel Murine Models of Cerebral Cavernous Malformations.
    Detter MR; Shenkar R; Benavides CR; Neilson CA; Moore T; Lightle R; Hobson N; Shen L; Cao Y; Girard R; Zhang D; Griffin E; Gallione CJ; Awad IA; Marchuk DA
    Angiogenesis; 2020 Nov; 23(4):651-666. PubMed ID: 32710309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mural Cell-Specific Deletion of Cerebral Cavernous Malformation 3 in the Brain Induces Cerebral Cavernous Malformations.
    Wang K; Zhang H; He Y; Jiang Q; Tanaka Y; Park IH; Pober JS; Min W; Zhou HJ
    Arterioscler Thromb Vasc Biol; 2020 Sep; 40(9):2171-2186. PubMed ID: 32640906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Propranolol or Beta-Blockers for Cerebral Cavernous Malformation: a Systematic Review and Meta-analysis of Literature in Both Preclinical and Clinical Studies.
    Ikramuddin S; Liu S; Ryan D; Hassani S; Hasan D; Feng W
    Transl Stroke Res; 2023 Oct; ():. PubMed ID: 37857790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concepts and hypotheses: inflammatory hypothesis in the pathogenesis of cerebral cavernous malformations.
    Shenkar R; Shi C; Check IJ; Lipton HL; Awad IA
    Neurosurgery; 2007 Oct; 61(4):693-702; discussion 702-3. PubMed ID: 17986930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebral cavernous malformation development in chronic mouse models driven by dual recombinases induced gene deletion in brain endothelial cells.
    Yang X; Dai Z; Gao C; Yin Y; Shi C; Liu R; Zhuge Q; Huang Y; Zhou B; Han Z; Zheng X
    J Cereb Blood Flow Metab; 2022 Dec; 42(12):2230-2244. PubMed ID: 35686705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in Cerebral Cavernous Malformation type 1.
    Choquet H; Trapani E; Goitre L; Trabalzini L; Akers A; Fontanella M; Hart BL; Morrison LA; Pawlikowska L; Kim H; Retta SF
    Free Radic Biol Med; 2016 Mar; 92():100-109. PubMed ID: 26795600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Towards precision nanomedicine for cerebrovascular diseases with emphasis on Cerebral Cavernous Malformation (CCM).
    Perrelli A; Fatehbasharzad P; Benedetti V; Ferraris C; Fontanella M; De Luca E; Moglianetti M; Battaglia L; Retta SF
    Expert Opin Drug Deliv; 2021 Jul; 18(7):849-876. PubMed ID: 33406376
    [No Abstract]   [Full Text] [Related]  

  • 33. Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu.
    Zhang D; Kinloch AJ; Srinath A; Shenkar R; Girard R; Lightle R; Moore T; Koskimäki J; Mohsin A; Carrión-Penagos J; Romanos S; Shen L; Clark MR; Shi C; Awad IA
    J Autoimmun; 2020 Sep; 113():102469. PubMed ID: 32362501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KRIT1: A Traffic Warden at the Busy Crossroads Between Redox Signaling and the Pathogenesis of Cerebral Cavernous Malformation Disease.
    Perrelli A; Ferraris C; Berni E; Glading AJ; Retta SF
    Antioxid Redox Signal; 2023 Mar; 38(7-9):496-528. PubMed ID: 36047808
    [No Abstract]   [Full Text] [Related]  

  • 35. Multidrug-Loaded Lipid Nanoemulsions for the Combinatorial Treatment of Cerebral Cavernous Malformation Disease.
    Perrelli A; Bozza A; Ferraris C; Osella S; Moglia A; Mioletti S; Battaglia L; Retta SF
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics and risk factors of cerebral cavernous malformation-related epilepsy.
    Zhang P; Zhang H; Shi C; Zhou J; Dong J; Liang M; Li R; Cheng J; Chen Y; Yuan J; Chen Y
    Epilepsy Behav; 2023 Feb; 139():109064. PubMed ID: 36640483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebral Cavernous Malformation: Immune and Inflammatory Perspectives.
    Tu T; Peng Z; Ren J; Zhang H
    Front Immunol; 2022; 13():922281. PubMed ID: 35844490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Variants in FCGR2A, PTPN2, and GM-CSF with Cerebral Cavernous Malformation: Potential Biomarkers for a Symptomatic Disease.
    da Fontoura Galváo G; Fontes-Dantas FL; da Silva EV; Alves-Leon SV; de Souza JM
    Curr Neurovasc Res; 2021; 18(2):172-180. PubMed ID: 34082682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel PKD1 Mutation Associated With Autosomal Dominant Kidney Disease and Cerebral Cavernous Malformation.
    Thomas C; Zühlsdorf A; Hörtnagel K; Mulahasanovic L; Grauer OM; Kümpers P; Wiendl H; Meuth SG
    Front Neurol; 2018; 9():383. PubMed ID: 29887830
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.